Home > Cardiology > ACC 2021 > Prevention and Health Promotion > STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids

STRENGTH trial fails to demonstrate cardioprotective effect of omega-3 fatty acids

Presented By
Dr Steven Nissen, Cleveland Clinic, USA
Conference
ACC 2021
Trial
STRENGTH, REDUCE-IT
Elevated levels of eicosapentaenoic acid (EPA) were not associated with a reduced risk of major adverse cardiac events (MACE) in a post-hoc analysis of the STRENGTH trial data [1]. Additionally, elevated levels of docosahexaenoic acid (DHA) were not associated with any harm. Controversy has surrounded the putative ability of omega-3 fatty acids EPA and DHA to protect against MACE. The REDUCE-IT trial (NCT01492361) reported that participants (n=8,179) who took 2 g of icosapent ethyl twice daily had a lower risk of ischaemic events than those who took a placebo (HR 0.75; 95% CI 0.68–0.83; P<0.001) [2]. In contrast, the STRENGTH trial (NCT02104817) (n=13,078) reported that 4 g a day of omega-3 carboxylic acid (CA) did not reduce ischaemic...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on